Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Pathway Traces Gene and Protein Activation in Breast Cancer

By LabMedica International staff writers
Posted on 17 Nov 2008
Cancer researchers have traced the molecular trail that links the ErbB2 (Her2/neu epidermal growth receptor family) oncogene to development of breast cancer via the activity of the Notch signaling pathway and its regulation of cyclin D1.

Approximately 25-30% of breast cancers have an amplification of the ErbB2 gene or overexpression of its protein product. More...
Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. The associated Notch gene belongs to a family of epidermal growth factor (EGF) like genes, which encode transmembrane proteins with a variable number of cysteine-rich EGF-like repeats in the extracellular region. Four notch genes have been described in mammals, which have been implicated in the differentiation of the nervous system and other structures.

According to results published in the September 10, 2008, online edition of the journal Clinical and Translational Science cyclin D1 is the critical connection between ErbB2 and Notch. The cyclin D protein belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Mutations, amplification, and overexpression of this gene, which alters cell cycle progression, were observed frequently in a variety of tumors and might contribute to tumorigenesis.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) used two methods to suppress cyclin D1 expression in a laboratory mouse population. Either deletion of cyclin D1 was obtained by genetic engineering, or small interfering RNA (siRNA) was used to silence cyclin D1 expression. In either case, Notch signaling was reduced. Reintroduction of cyclin D1 into cyclin D1-deficient cells restored Notch1 activity through the inhibition of a protein called Numb, which is an endogenous inhibitor of Notch1 activity.

"Breast and other cancers are maintained through a population of cancer stem cells. By specifically targeting cancer stem cells we hope to reduce recurrence and improve therapy responses,” said senior author Dr. Richard Pestell, professor of cancer biology at Thomas Jefferson University.

Progressing towards that goal, this study has shown that cyclin D1 functions downstream as a genetic target of Notch1 and amplifies Notch1 activity by repressing Numb. This outlines a novel pathway by which ErbB2 induces Notch1 activity via the induction of cyclin D1.

Related Links:
Thomas Jefferson University


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.